CL2016002368A1 - Compounds derived from benzamide, inhibitors of wnt signaling pathways; intermediary compounds; compositions and pharmacological combinations; useful for the prevention or treatment of polyposis coli, osteoporosispseudoglioma syndrome, exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra amelia syndrome, type 2 diabetes mellitus, fragile syndrome, solid tumors, among others. - Google Patents

Compounds derived from benzamide, inhibitors of wnt signaling pathways; intermediary compounds; compositions and pharmacological combinations; useful for the prevention or treatment of polyposis coli, osteoporosispseudoglioma syndrome, exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra amelia syndrome, type 2 diabetes mellitus, fragile syndrome, solid tumors, among others.

Info

Publication number
CL2016002368A1
CL2016002368A1 CL2016002368A CL2016002368A CL2016002368A1 CL 2016002368 A1 CL2016002368 A1 CL 2016002368A1 CL 2016002368 A CL2016002368 A CL 2016002368A CL 2016002368 A CL2016002368 A CL 2016002368A CL 2016002368 A1 CL2016002368 A1 CL 2016002368A1
Authority
CL
Chile
Prior art keywords
syndrome
compounds
benzamide
tetra
inhibitors
Prior art date
Application number
CL2016002368A
Other languages
Spanish (es)
Inventor
Kai Thede
Eckhard Bender
William Scott
Anja Giese
Ludwig Zorn
Ningshu Liu
Ursula Mönning
Franziska Siegel
Stefan Golz
Andrea Hägebarth
Philip Lienau
Florian Puehler
Daniel Basting
Dirk Schneider
Manfred Möwes
Jens Geisler
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2016002368A1 publication Critical patent/CL2016002368A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de benzamida, inhibidores de las vías de señalización de WNT; compuestos intermediarios; composiciones y combinaciones farmacológicas; útiles para la prevención o tratamiento de poliposis coli, síndrome de osteoporosispseudoglioma, vitreorretinopatía exudativa, angiogénesis retinal, enfermedad coronaria temprana, síndrome tetra Amelia, diabetes mellitus tipo 2, síndrome de frágil, tumores sólidos, entre otras.Compounds derived from benzamide, inhibitors of WNT signaling pathways; intermediary compounds; compositions and pharmacological combinations; useful for the prevention or treatment of polyposis coli, osteoporosispseudoglioma syndrome, exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra Amelia syndrome, type 2 diabetes mellitus, fragile syndrome, solid tumors, among others.

CL2016002368A 2014-03-20 2016-09-20 Compounds derived from benzamide, inhibitors of wnt signaling pathways; intermediary compounds; compositions and pharmacological combinations; useful for the prevention or treatment of polyposis coli, osteoporosispseudoglioma syndrome, exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra amelia syndrome, type 2 diabetes mellitus, fragile syndrome, solid tumors, among others. CL2016002368A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968172P 2014-03-20 2014-03-20
EP14185274 2014-09-18

Publications (1)

Publication Number Publication Date
CL2016002368A1 true CL2016002368A1 (en) 2017-03-03

Family

ID=65628886

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002368A CL2016002368A1 (en) 2014-03-20 2016-09-20 Compounds derived from benzamide, inhibitors of wnt signaling pathways; intermediary compounds; compositions and pharmacological combinations; useful for the prevention or treatment of polyposis coli, osteoporosispseudoglioma syndrome, exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra amelia syndrome, type 2 diabetes mellitus, fragile syndrome, solid tumors, among others.

Country Status (5)

Country Link
CL (1) CL2016002368A1 (en)
IL (1) IL247327A0 (en)
MA (1) MA39762A (en)
SV (1) SV2016005282A (en)
ZA (1) ZA201605726B (en)

Also Published As

Publication number Publication date
SV2016005282A (en) 2018-12-05
MA39762A (en) 2017-01-25
IL247327A0 (en) 2016-09-29
ZA201605726B (en) 2019-11-27

Similar Documents

Publication Publication Date Title
CY1121938T1 (en) 4-HYDROXY-3-(HETERORYL)PYRIDINO-2-ONE APJ AGENTS FOR USE IN THE TREATMENT OF CARDIAC DISORDERS
CO2019000386A2 (en) Heterocyclic compounds as immunomodulators
MX2018003161A (en) Methods for treating arenaviridae and coronaviridae virus infections.
EA201692177A1 (en) CONNECTIONS AND COMPOSITIONS AS AN AGONISTS OF TOLL-LIKE RECEPTOR 7
MX2016014308A (en) COMPOUNDS AND COMPOSITIONS AS AGENTS OF THE TOLL TYPE RECEIVER 7.
CR20160456A (en) FIBERATED BIBYCLIC HETEROARILE OR ARILO COMPOUNDS
TN2018000369A1 (en) AROMATIC SULFONAMIDE DERIVATIVES.
MX377916B (en) 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS.
MX2017002670A (en) Glycosidase inhibitors.
MX372997B (en) AMINOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS.
CL2015000880A1 (en) Heterocyclic compounds derived from 4-pyrimidinone, hiv reverse transcriptase inhibitors; pharmaceutical composition; use in the prophylaxis or treatment of hiv infection or for the prophylaxis, treatment or delay of the onset of AIDS in a subject.
CL2015001536A1 (en) Compounds derived from pyridine, cannabinoid receptor agonists 2; synthesis process; its use for the treatment or prophylaxis of pain, atherosclerosis, diabetic retinopathy, myocardial infarction, stroke, among others.
CL2015002529A1 (en) Tetrahydropyrrolothiazine Compounds
MX376062B (en) MUSCARINIC RECEPTOR AGONISTS.
MX2017006224A (en) Heterocyclic derivatives and use thereof.
UY37182A (en) INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE VIRAL REPLICATION OF DENGUE
CL2015001279A1 (en) Compounds derived from pyridine, urate transporter inhibitors urat 1; pharmaceutical composition that includes them; use for the treatment or prevention of diseases such as gout, hyperuricemia, hypertension, kidney diseases, among others.
MX2021011507A (en) PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS.
MX389724B (en) PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS
MX2016013801A (en) MODULATORS OF THE RECEPTOR COUPLED TO PROTEIN G 40 (GPR40) OF PIRROLIDINE FOR THE TREATMENT OF DISEASES LIKE DIABETES.
EA201790519A1 (en) THERAPEUTIC CONNECTIONS AS INTEGRATORS OF OREXIN-1 RECEPTOR
UY36145A (en) Compounds of 1, 3, 4-thiadiazole and use thereof for the treatment of cancer
CU20200038A7 (en) COMPOUNDS DERIVED FROM PYRAZOLO-PIRROLO-PYRIMIDINE-DIONA AS INHIBITORS OF P2X3
UY37466A (en) N-HYDROXIAMIDINHETEROCICLES SUBSTITUTED AS MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE
CL2015003195A1 (en) Purine derivatives as cb2 receptor agonists.